Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Parexel Partners with CTC North to Increase Research Capacity for Delivery of Early Phase Clinical Trials | ||
| By: GlobeNewswire - 23 Nov 2020 | Back to overview list |
|
BOSTON and DURHAM, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, today announced a strategic partnership between its Early Phase Clinical Unit (EPCU) in Berlin, Germany and Clinical Trial Center (CTC) North, a full-service CRO located at the University Medical Center Hamburg-Eppendorf (UKE). The strategic collaboration supports the high demand for and continuation of Early Phase clinical studies during the COVID-19 pandemic, enabling the optimal use of resources and providing additional bed capacity for healthy volunteers and patients ensuring early phase research can continue. One central point of the collaboration will be the roll-out and implementation of Parexel’s eSource system ClinBaseTM at CTC North to drive efficiency and collaboration. “We’re delighted about the CTC North partnership, which leverages broad expertise across both partners to provide a unique solution for Clinical Pharmacology research in healthy volunteers and patients,” said Dr. Sandra Stark, Head of the Berlin EPCU & Interim Head, Global EPCUs. “The use of ClinBase as the eSource system will support trials from a data perspective resulting in minimal timelines for post-clinical services.” Multiple ongoing and recently awarded studies are being conducted at CTC North as well as biosimilar, COVID-19, food effect and bioavailability studies, among others. CTC North and its Clinical Pharmacology Unit have partnered with UKE for more than 10 years, primarily in the conduct of vaccine development and first-in-human trials. “We’re pleased to have the opportunity to partner with Parexel’s Berlin EPCU after collaborating together for many years,” said Ralf Freese, Medical Director and Vice President of BVMA (Federal Association of Contract Research Organizations). “Under one roof, we’re combining Parexel’s ‘excellence’ with CTC North’s access to one of Europe´s most modern clinics at UKE providing access to specialists from all fields of medicine.” In addition to its Berlin EPCU, Parexel’s Early Phase clinical development presence includes EPCUs in Baltimore and Los Angeles (USA) and London (United Kingdom), providing access to more than 300 beds and 35+ patient populations. This global network enables customers to run Phase I trials from multiple locations simultaneously with integrated technology to make decisions in real-time. During the COVID-19 pandemic, Parexel has adapted its Early Phase facilities and processes to mitigate viral transmission risks. Each of the company’s units can support COVID-19- related product development and flexible capacity models and decentralized clinical trial processes have been introduced where possible to help advance Early Phase programs in support of COVID-19 therapies. About Parexel About CTC North CONTACT: Parexel W2O |
||
|
|
||
 | Back to overview list | |